source
- FDA approves Zenocutuzumab for NRG1 fusion-positive advanced cholangiocarcinomaThe U.S. Food and Drug Administration has granted approval for zenocutuzumab-zbco, marketed as Bizengri, to treat adult patients with NRG1 fusion‑positive advanced, unresectable or metastatic chola…
- Giants of Cancer Care Unveils 14th Annual Class of Oncology InnovatorsOncLive announced the 14th Annual Giants of Cancer Care inductees, a program that honors oncology leaders whose research, education, mentorship and patient‑focused work have reshaped cancer treatme…